RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Immunotech Biopharm of Beijing has released its initial prospectus for a Hong Kong IPO, an offering expected to raise up to $200 million. The company’s lead product, EAL, consists of autologous CD8+ T cells activated and expanded ex vivo. EAL is currently being tested in a China Phase II trial in patients with post-surgical liver cancer. Immunotech, which hopes EAL will be ready for a 2021 launch, is also working on pre-clinical development of nine CAR-T candidates.
